Figures

Printed version


Figure 1: Variety of ‘national drugs strategies’

Figure 2: Member States in which selective prevention (i.e. targeting vulnerable populations or areas) is mentioned in strategies and implemented

Figure 3: Member States in which quality control, monitoring and evaluation of school-based prevention are considered a priority and are carried out

Figure 4: Changing patterns of diffusion of cannabis initiation by selected birth cohorts – the example of Spain

Figure 5: Recent use (past year) of cannabis among young adults (15–34 years) as measured by national population surveys

Figure 6: Prevalence of ‘heavy’ cannabis use among 15-year-old school students by gender in 2001/2002

Figure 7: Recent use (past year) of amphetamines, ecstasy and cocaine among young adults (aged 15–34) as measured by national population surveys

Figure 8: Recent use (past year) of ecstasy among all adults (aged 15–64), young adults (aged 15–34) and younger males (aged 15–24) as measured by national population surveys

Figure 9: Prevalence of cocaine use (past year) among young adults in some EU countries as measured by population surveys

Figure 10: Number of drug mentions in hospital emergency episodes, by drug type, Barcelona, 1992–2002

Figure 11: Estimated rate of problem drug use (rate per 1 000 aged 15–64)

Figure 12: Estimated rate of injecting drug use (rate per 1 000 aged 15–64)

Figure 13: Reported newly diagnosed cases of HIV infection among IDUs per million population in some new EU Member States

Figure 14: HIV prevalence among injecting drug users – studies with national and local coverage 2001–2003

Figure 15: HCV prevalence among injecting drug users – studies with national and local coverage 2001–2002

Figure 16: Proportion of drug-related deaths with or without the presence of opiates in some EU countries in 2001–2002 (1)

Figure 17: Mean age of drug-related death victims in some EU countries, 1990–2002

Figure 18: Changes in the number of acute drug-related deaths – EU and Norway total 1990–2001 (indexed to 100 for the average over the period 1990–2001)

Figure 19: Quality assurance of drug-related treatment

Figure 20: Proportion of new clients attending drug treatment services who report primary drug to be heroin, cocaine and cannabis, 1996–2002

Figure 21: New clients attending drug treatment in 2002 – distribution by different primary drugs

Figure 22: Distribution of route of administration for heroin, cocaine and other stimulants among attendees at outpatient treatment services, 2000–2002

Figure 23: Levels of evaluation in ‘national drugs strategies’

Figure 24: Evaluation as a cyclical process

Figure 25: Main characteristics of a structured drug policy approach

Figure 26: Reported primary drug among new and all clients attending drug treatment services in 2002

Figure 27: Cannabis as reported primary drug among new clients attending treatment in 2002

Figure 28: Trends in cannabis as reported primary drug among new clients attending treatment, 1996–2002

Figure 29: Distribution of reported primary drug among outpatient treatment attendees, by age group (2002)

Figure 30: Distribution of frequency of use of reported primary drug among all outpatient treatment attendees in 2002

Figure 31: Proportion of ‘daily users or almost daily users’ of cannabis among all adults and young adults in some EU countries, measured by national population surveys


Online version


Figure 1 OL: National plans specifying prevention contents and strategies

Figure 2 OL: Delivery modes of school-based prevention

Figure 3 OL: Prevention for youth outside schools

Figure 4 OL: Relative frequency of cannabis use among 15-year-old school students who used during past year

Figure 5 OL: Evolution of cannabis use among young people in some EU countries measured by population surveys

Figure 6 OL: Evolution of recent use (past year) of amphetamines and ecstasy among young adults (15–34 years old) in the United Kingdom

Figure 7 OL: Proportion of mentions in hospital emergency episodes due to acute reaction to drugs, Spain 1996–2001

Figure 8 OL: Importance given in Member States to prevention responses in recreational settings

Figure 9 OL: Trends in injecting drug use

Figure 10 OL: Evolution of the proportion of people over 35 years among victims of acute drug-related deaths in the EU countries from 1990(1) until 2001–02

Figure 11 OL: Long-term EU trend in acute deaths directly related to drug use (1985–2001)

Figure 12 OL: Trends in acute drug-related deaths in the different EU countries

Figure 13 OL: Inpatient drug-free treatment modes

Figure 14 OL: Substitution treatment or drug-free treatment predominance for opiate use

Figure 15 OL: Introduction of methadone treatment in the EU

Figure 16 OL: Overview of social reintegration provision

Figure 17 OL: New clients in treatment by year in some EU countries

Figure 18 OL: Age at first use by main drug

Figure 19 OL: All clients by level of education

Figure 20 OL: All clients by labour status

Figure 21a OL: Living conditions (where) among all clients

Figure 21b OL: Living conditions (with whom) among all clients

Figure 22 OL: Source of referral among all clients: for all drugs and for cannabis

Figure 23 OL: Labour status among cannabis clients and all clients

Figure 24 OL: Living conditions among cannabis clients and all clients

Figure 25 OL: Frequency of cannabis use by country

Figure 26 OL: Most used secondary drug among all cannabis clients by country

Figure 27 OL: Source of referrals among all clients

Figure 28 OL: Frequency of use among all cannabis clients

Figure 29 OL: Proportion of daily (or almost daily) users among adults (15–64 years old) who used cannabis in the previous month